Biomarker and testing questions
Ask whether CD20 expression and pathology review support the treatment.
Second-opinion questions
Does the pathology report confirm the marker and disease subtype that make this treatment appropriate?
Safety discussion reminder
Infusion reactions and infection risks should be reviewed with the treating team.
Official source links
- NCI cancer drug information (NCI)
- DailyMed label search (DailyMed)
- FDA label search (FDA)
- ClinicalTrials.gov search (ClinicalTrials.gov)